Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer
OBTCPAN
Interobserver Variability In The Assessment Of Vascular Invasion In Pancreatic Cancer
1 other identifier
observational
138
1 country
1
Brief Summary
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of subjective interpretation by observers implying a fundamental variation in patient's treatments and an irreproducibility of different center study results. This is a multicenter diagnostic study on interobserver agreement on the resectability of pancreatic cancer based upon NCCN criteria. The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification). One hundred and thirty eight consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan will be enrolled. 69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will be randomly selected from a pool of 138 of the patients that meet the inclusion criteria. Each study will be independently reviewed by a senior radiologist and a senior surgeon of each center, blinded to patient's clinical history and CT scan report, using NCCN definition of respectability status. A CFR will be filled during the review and send to the study coordinator. The data will be than centrally analyzed to asses interobserver agreement The enrolment phase will last 6 months and the whole study will last 8 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 5, 2018
CompletedFirst Submitted
Initial submission to the registry
September 12, 2018
CompletedFirst Posted
Study publicly available on registry
September 17, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 5, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
May 5, 2019
CompletedDecember 13, 2018
December 1, 2018
6 months
September 12, 2018
December 11, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of interobserver variability to define vascular invasion and resectability status on CT scans
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
Eight months
Secondary Outcomes (1)
Identification of disagreement causes and proposal of a new classification system
One year
Eligibility Criteria
138 Consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan.
You may qualify if:
- Age \> 18 years
- Non-metastatic pancreatic adenocarcinoma
- Availability of contrast enhanced CT scan with adequate quality. Section thickness must be \<3 mm, according to NCCN recommendations
- Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated.
- Signed informed consent
You may not qualify if:
- Evidence of metastatic disease
- Inadequate quality CT scan (non-respecting the NCCN recommendations)
- Absence of cytology/histology confirmation
- Refusal to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ospedale San Raffaele
Milan, 20132, Italy
Study Officials
- PRINCIPAL INVESTIGATOR
Gianpaolo Balzano, MD
Ospedale San Raffaele
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 12, 2018
First Posted
September 17, 2018
Study Start
September 5, 2018
Primary Completion
March 5, 2019
Study Completion
May 5, 2019
Last Updated
December 13, 2018
Record last verified: 2018-12
Data Sharing
- IPD Sharing
- Will not share